✦ LIBER ✦

A Benefit-Risk Assessment of Class III Antiarrhythmic Agents

✍ Scribed by Dr Bente Brendorp, Ole Dyg Pedersen, Christian Torp-Pedersen, Naji Sahebzadah, Lars Køber

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Risk and Benefit Class III Antiarrhythmi

📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB

In vivo assessment of class III agents a

✍ J. K. Gibson; J. A. Kersten 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 650 KB

Sotalol: A unique class III antiarrhythm

✍ John B. Barlow; Israel W.P. Obel; Wendy A. Pocock; Joseph K. McKibbin 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 300 KB

Ibutilide: A New Class III Antiarrhythmi

✍ Dr. Jacquelyn S. Cropp; Dr. Ellen G. Antal; Dr. Robert L. Talbert 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 818 KB

Dofetilide, a New Class III Antiarrhythm

✍ Thomas L. Lenz; Daniel E. Hilleman 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Dofetilide: a new class III antiarrhythm

✍ Roukoz, Henri; Saliba, Walid 📂 Article 📅 2007 🏛 Expert Reviews 🌐 English ⚖ 418 KB